PRODUCTYUTREPIA™

YUTREPIA™ (treprostinil) inhalation powder is an investigational, inhaled dry powder formulation of treprostinil delivered through a proven, convenient, palm-sized device. On November 5, 2021, the FDA issued a tentative approval for YUTREPIA, which is indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability in adult patients with New York Heart Association (NYHA) Functional Class II-III symptoms. YUTREPIA was designed using Liquidia’s PRINT® technology, which enables the development of drug particles that are precise and uniform in size, shape, and composition, and that are engineered for optimal deposition in the lung following oral inhalation.

Treprostinil Injection is the first-to-file, fully substitutable generic treprostinil for parenteral administration. Treprostinil Injection contains the same active ingredient, same strengths, same dosage form and same inactive ingredients as Remodulin® (treprostinil) and is offered to patients and physicians with the same level of service and support, but at a lower price than the branded drug. Liquidia PAH promotes the appropriate use of Treprostinil Injection for the treatment of PAH in the United States in partnership with its commercial partner, who holds the Abbreviated New Drug Application (ANDA) with the FDA.

Background

In January 2023, HCRx and Liquidia Corporation (Liquidia) announced a non-dilutive financing of up to $100 million. Under the terms of the agreement, Liquidia received $32.5 million at closing and under subsequent amendments, HCRx funded an additional $67.5 million across three tranches. This financing and the additional tranches provide capital to support the potential launch of YUTREPIA™ (treprostinil) inhalation powder for the potential treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), the continued development of YUTREPIA in other clinical trials, including trials for pediatric patients and trials further evaluating the use of YUTREPIA in WHO Group 1 and WHO Group 3 patients, and the June 2023 in-license of the exclusive North American rights to an inhaled liposomal formulation of Treprostinil, L606, and its clinical development.